{"id":"hexachlorophene","rwe":[{"pmid":"41850441","year":"2026","title":"Halogenated phenolic disinfectants suppress 11β-hydroxysteroid dehydrogenase 2 activity in human and rat models: Experimental and computational evidence.","finding":"","journal":"The Journal of steroid biochemistry and molecular biology","studyType":"Clinical Study"},{"pmid":"41780647","year":"2026","title":"The zebrafish visual and acoustic motor response (VAMR) assay has the potential to add value to the developmental neurotoxicity in Vitro battery (DNT IVB).","finding":"","journal":"Neurotoxicology","studyType":"Clinical Study"},{"pmid":"41361996","year":"2026","title":"Trans-Golgi network-associated noncanonical autophagy depends on the V-ATPase-ATG16L1 axis and mediates IL1B secretion.","finding":"","journal":"Autophagy","studyType":"Clinical Study"},{"pmid":"41308746","year":"2026","title":"An ELISA for discovering protein-protein interaction inhibitors: Blocking lysinoalanine crosslinking between subunits of the spirochete flagellar hook as a test case.","finding":"","journal":"SLAS discovery : advancing life sciences R & D","studyType":"Clinical Study"},{"pmid":"41279933","year":"2025","title":"An ELISA for discovering protein-protein interaction inhibitors: blocking lysinoalanine crosslinking between subunits of the spirochete flagellar hook as a test case.","finding":"","journal":"bioRxiv : the preprint server for biology","studyType":"Clinical Study"}],"tags":[{"label":"Antiseptic","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Mitogen-activated protein kinase 14","category":"target"},{"label":"MAPK14","category":"gene"},{"label":"ESR2","category":"gene"},{"label":"MAPK1","category":"gene"},{"label":"D08AE01","category":"atc"},{"label":"Off-Patent","category":"patent"},{"label":"Active","category":"status"},{"label":"Davis And Geck","category":"company"},{"label":"Approved 1940s","category":"decade"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Anti-Infective Agents, Local","category":"pharmacology"}],"phase":"marketed","safety":{"contraindications":["Breastfeeding (mother)","Burn injury","CNS Toxicity","Denuded skin"]},"trials":[],"aliases":[],"company":"Davis And Geck","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=HEXACHLOROPHENE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T04:58:09.341433+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T04:58:25.349537+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T04:58:15.218088+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=HEXACHLOROPHENE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T04:58:15.527657+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Bacterial enoyl-[acyl-carrier-protein] reductase inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T04:58:16.577978+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL496/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T04:58:16.240948+00:00"}},"allNames":"pre-op","offLabel":[],"synonyms":["hexachlorophene","almederm","dermadex","exofene","hexachlorofen","hexachlorophen","hexophene"],"timeline":[{"date":"1949-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from SANOFI AVENTIS US to Davis And Geck"},{"date":"1949-04-19","type":"positive","source":"DrugCentral","milestone":"FDA approval (Sanofi Aventis Us)"},{"date":"1984-11-30","type":"positive","source":"FDA Orange Book","milestone":"Turgex approved — 3%"}],"aiSummary":"HEXACHLOROPHENE (Pre-Op), marketed by Davis And Geck, is an antiseptic agent used primarily for pre-operative skin preparation. Its key strength lies in its mechanism of action, which effectively disrupts the cell membranes of bacteria and other microorganisms, leading to their death. The primary risk is the upcoming key patent expiry in 2028, which could lead to increased competition from generic alternatives.","approvals":[{"date":"1949-04-19","orphan":false,"company":"SANOFI AVENTIS US","regulator":"FDA"}],"brandName":"Pre-Op","ecosystem":[],"mechanism":{"target":"N-acyl-phosphatidylethanolamine-hydrolyzing phospholipase D, 78 kDa glucose-regulated protein, Adenosine receptor A3","novelty":"Follow-on","targets":[{"gene":"MAPK14","source":"DrugCentral","target":"Mitogen-activated protein kinase 14","protein":"Mitogen-activated protein kinase 14"},{"gene":"ESR2","source":"DrugCentral","target":"Estrogen receptor beta","protein":"Estrogen receptor beta"},{"gene":"MAPK1","source":"DrugCentral","target":"Mitogen-activated protein kinase 1","protein":"Mitogen-activated protein kinase 1"},{"gene":"ADORA3","source":"DrugCentral","target":"Adenosine receptor A3","protein":"Adenosine receptor A3"},{"gene":"PTGS2","source":"DrugCentral","target":"Prostaglandin G/H synthase 2","protein":"Prostaglandin G/H synthase 2"},{"gene":"EGFR","source":"DrugCentral","target":"Epidermal growth factor receptor","protein":"Epidermal growth factor receptor"},{"gene":"ADORA2A","source":"DrugCentral","target":"Adenosine receptor A2a","protein":"Adenosine receptor A2a"},{"gene":"ADRA2C","source":"DrugCentral","target":"Alpha-2C adrenergic receptor","protein":"Alpha-2C adrenergic receptor"},{"gene":"CYP2C19","source":"DrugCentral","target":"Cytochrome P450 2C19","protein":"Cytochrome P450 2C19"},{"gene":"CYP1A2","source":"DrugCentral","target":"Cytochrome P450 1A2","protein":"Cytochrome P450 1A2"}],"modality":"Small Molecule","drugClass":"Antiseptic","explanation":"","oneSentence":"","technicalDetail":"Pre-Op (HEXACHLOROPHENE) exerts its antiseptic effects by interacting with the cell membranes of microorganisms, ultimately leading to the disruption of membrane function and the death of the organism."},"commercial":{"launchDate":"1949","_launchSource":"DrugCentral (FDA 1949-04-19, SANOFI AVENTIS US)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1364","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=HEXACHLOROPHENE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=HEXACHLOROPHENE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T14:58:45.423907","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T04:58:25.349630+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"phenol","drugSlug":"phenol","fdaApproval":"","relationship":"same-class"},{"drugName":"triclosan","drugSlug":"triclosan","fdaApproval":"1997-07-11","relationship":"same-class"},{"drugName":"chloroxylenol","drugSlug":"chloroxylenol","fdaApproval":"","relationship":"same-class"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"hexachlorophene","indications":{"approved":[],"offLabel":[],"pipeline":[]},"currentOwner":"Davis And Geck","drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"phenol","brandName":"phenol","genericName":"phenol","approvalYear":"","relationship":"same-class"},{"drugId":"triclosan","brandName":"triclosan","genericName":"triclosan","approvalYear":"1997","relationship":"same-class"},{"drugId":"chloroxylenol","brandName":"chloroxylenol","genericName":"chloroxylenol","approvalYear":"","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT00532324","phase":"NA","title":"A Prospective Cohort Pilot Study of the Clinical and Molecular Epidemiology of Staphylococcus Aureus in Pregnant Women at the Time of Group B Streptococcal Screening in a Large Urban Medical Center in Chicago, IL USA","status":"COMPLETED","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2008-02","conditions":["Staphylococcus Aureus"],"enrollment":107,"completionDate":"2013-10"},{"nctId":"NCT00631566","phase":"NA","title":"Prospective Study of Methicillin-Resistant Staphylococcus Aureus (MRSA) Among HIV-Infected Persons","status":"COMPLETED","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2007-05","conditions":["HIV Infections","Staphylococcal Infections"],"enrollment":550,"completionDate":"2017-10"},{"nctId":"NCT01049438","phase":"NA","title":"A Prospective Trial of Nasal Mupirocin, Hexachlorophene Body Wash, and Systemic Antibiotics for Prevention of Recurrent Methicillin Resistant Staphylococcus Aureus Infections","status":"COMPLETED","sponsor":"Natividad Medical Center","startDate":"2006-08","conditions":["Methicillin Resistant Staphylococcus Aureus Skin Infections"],"enrollment":31,"completionDate":"2009-09"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"_patentsChecked":true,"crossReferences":{"NUI":"N0000146582","MMSL":"4826","NDDF":"003176","UNII":"IWW5FV6NK2","VUID":"4018252","CHEBI":"CHEBI:5693","VANDF":"4018252","INN_ID":"2033","RXNORM":"5293","UMLSCUI":"C0019435","chemblId":"CHEMBL496","ChEMBL_ID":"CHEMBL496","KEGG_DRUG":"D00859","DRUGBANK_ID":"DB00756","PUBCHEM_CID":"3598","SNOMEDCT_US":"1878008","IUPHAR_LIGAND_ID":"11069","MESH_DESCRIPTOR_UI":"D006582"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1949-","companyName":"Sanofi","relationship":"Original Developer"},{"period":"present","companyName":"Davis And Geck","relationship":"Current Owner"}],"publicationCount":860,"therapeuticAreas":["Infectious Disease"],"atcClassification":{"source":"DrugCentral","atcCode":"D08AE01","allCodes":["D08AE01"]},"biosimilarFilings":[],"originalDeveloper":"Sanofi Aventis Us","recentPublications":[{"date":"2026 Mar 16","pmid":"41850441","title":"Halogenated phenolic disinfectants suppress 11β-hydroxysteroid dehydrogenase 2 activity in human and rat models: Experimental and computational evidence.","journal":"The Journal of steroid biochemistry and molecular biology"},{"date":"2026 Mar 2","pmid":"41780647","title":"The zebrafish visual and acoustic motor response (VAMR) assay has the potential to add value to the developmental neurotoxicity in Vitro battery (DNT IVB).","journal":"Neurotoxicology"},{"date":"2026 Apr","pmid":"41361996","title":"Trans-Golgi network-associated noncanonical autophagy depends on the V-ATPase-ATG16L1 axis and mediates IL1B secretion.","journal":"Autophagy"},{"date":"2026 Feb","pmid":"41308746","title":"An ELISA for discovering protein-protein interaction inhibitors: Blocking lysinoalanine crosslinking between subunits of the spirochete flagellar hook as a test case.","journal":"SLAS discovery : advancing life sciences R & D"},{"date":"2025 Oct 31","pmid":"41279933","title":"An ELISA for discovering protein-protein interaction inhibitors: blocking lysinoalanine crosslinking between subunits of the spirochete flagellar hook as a test case.","journal":"bioRxiv : the preprint server for biology"}],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"withdrawn","companyName":"Davis And Geck","companyId":"davis-and-geck","modality":"Small molecule","firstApprovalDate":"1949","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1949-04-19T00:00:00.000Z","mah":"SANOFI AVENTIS US","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T04:58:25.349630+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}